Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.
At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry.
More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs.
Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved.
The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals.
Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products.
The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia.
For more information visit: https://www.cadilapharma.com/
Overview
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2026 | Notice of annual general meeting in EQL Pharma AB | Notice of annual general meeting in EQL Pharma AB Fri, Jul 17, 2026 10:15 CET Report this content The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 20 August 202... |
| Aug 18, 2025 | The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB | The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB Mon, Aug 18, 2025 11:00 CET Report this content Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has present... |
| Jul 22, 2025 | Notice of annual general meeting in EQL Pharma AB | Notice of annual general meeting in EQL Pharma AB Tue, Jul 22, 2025 10:00 CET Report this content The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 21 August 202... |
| Feb 24, 2025 | Nomination committee for the 2025 Annual General Meeting | Nomination committee for the 2025 Annual General Meeting Mon, Feb 24, 2025 09:24 CET Report this content According to the resolution of the 2024 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board... |
| Jul 16, 2024 | Notice of annual general meeting in EQL Pharma AB | Notice of annual general meeting in EQL Pharma AB Tue, Jul 16, 2024 07:00 CET Report this content The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Monday 19 August 2024 ... |
| May 21, 2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | |
| Mar 19, 2024 | Cadila Pharmaceuticals launches novel iron injection | Cadila Pharmaceuticals has launched a novel iron injection to addressIron Deficiency Anaemia. The product available as Redshot FCM -- fortified with the advanced Ferric Carboxymallose formulation --- is designed for administration to both a... |
| Mar 4, 2024 | Cadila Pharmaceuticals launches advanced Quadrivalent Influenza Vaccine | Cadila Pharmaceuticals on Monday launched the Cadiflu Tetra Vaccine, an advanced Quadrivalent Influenza Vaccine, to prevent influenza, a recurrent, widespread and debilitating viral infection. The vaccine is approved by DCGI for use in adul... |
| Mar 4, 2024 | Despite mental health benefits, over 50% women quit exercising: Study | Despite the clear connection between mental well-being and exercise, a study conducted by sportswear manufacturer ASICS found that over half of women globally are dropping out or stopping exercise completely, which is negatively impacting t... |
Reviews 0
FAQ about Cadila Pharmaceuticals
When was Cadila Pharmaceuticals founded?
Cadila Pharmaceuticals was founded in 1951.
What has the press written about Cadila Pharmaceuticals?
Parsers VC has collected 14 articles mentioning Cadila Pharmaceuticals, among them “Notice of annual general meeting in EQL Pharma AB” (Jul 17, 2026) and “The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB” (Aug 18, 2025).
Is Cadila Pharmaceuticals still active?
Yes, Cadila Pharmaceuticals is active; its latest activity on Parsers VC dates from Aug 7, 2026.